# OnCo record richter-transformation-cll (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/richter-transformation-cll/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "richter-transformation-cll" ;
  schema:name "Richter transformation of chronic lymphocytic leukaemia"@en ;
  schema:alternateName "Richter syndrome"@en, "Richter's transformation"@en, "CLL transformed to diffuse large B-cell lymphoma"@en, "Transformed CLL"@en ;
  schema:description "Richter transformation is the sudden change of slow chronic lymphocytic leukaemia into a fast-growing lymphoma, usually of the diffuse large B-cell type. It is treated with lymphoma chemotherapy followed by a donor transplant where possible, and newer drugs such as pirtobrutinib, venetoclax combinations and bispecific antibodies are being tested because standard chemotherapy rarely cures it."@en ;
  schema:url <https://onco.cc/cancers/richter-transformation-cll/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Richter%27s_transformation> ;
  schema:citation <https://en.wikipedia.org/wiki/Richter%27s_transformation>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/cll-treatment-naive/>, <https://onco.cc/cancers/cll-relapsed/>, <https://onco.cc/biomarkers/tp53-del17p/>, <https://onco.cc/biomarkers/double-hit-rearrangement/>, <https://onco.cc/biomarkers/ig-tcr-clonality/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/technologies/clonality-testing/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/myc-gene/>, <https://onco.cc/targets/cdkn2a/>, <https://onco.cc/targets/notch1/> ;
  onco:pathways <https://onco.cc/pathways/p53-mdm2-axis/>, <https://onco.cc/pathways/myc/>, <https://onco.cc/pathways/clonal-evolution/> ;
  onco:terms <https://onco.cc/terms/richter-transformation/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/terms/tp53-mutated/>, <https://onco.cc/terms/del17p-tp53/>, <https://onco.cc/terms/lymphoma-bio-transformation/>, <https://onco.cc/terms/deauville/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-rossi-richter-syndrome-blood-2018/>, <https://onco.cc/key-papers/paper-who-2022-lymphoid-alaggio-leukemia-2022/> ;
  onco:pipeline <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/trials/nct04623541/>, <https://onco.cc/trials/nct02029443/>, <https://onco.cc/technologies/car-t/> ;
  onco:standardOfCare <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/terms/richter-transformation/>, <https://onco.cc/terms/tp53-mutated/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/trials/nct04623541/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/trials/nct04623541/>, <https://onco.cc/trials/nct02029443/> .